Feature | May 11, 2010| Dave Fornell

Fluid Status Monitoring May Offer Early Heart Failure Warning

Monitoring congestive heart failure patients for any worsening in their condition is based mainly on patient compliance to accurately weigh themselves every day and report any unusual symptoms. A technology introduced on Medtronic implantable electrophysiology devices may help to more closely monitor patients and alert physicians to any fluid buildup in the lungs before the patient detects any changes.

OptiVol fluid status monitoring is found on Medtronic’s latest wireless defibrillators, including the Consulta and Concerto cardiac resynchronization therapy defibrillators (CRT-Ds), and the Secura and Virtuoso implantable cardioverter-defibrillators (ICDs).

The device was tested in the Fluid Accumulation Status Trial (FAST) FDA trial from 2006 to 2008. The principal investigator was William T. Abraham, M.D., FACC, professor of internal medicine and director of the division of cardiovascular medicine at the Ohio State University Medical Center (OSU), Columbus. He said it’s a simple principle, using ICDs, pacemakers and CRTs already implanted in the body to help monitor patients. The device passes a small current through the tip of a lead to measure the resistance to the flow of electrons through the chest. As the lungs fill with water, the resistance falls. This sends an alert via Medtronic’s Carelink remote device monitoring system, or is detected with a wand during patient follow-up.

The study compared the device index to the gold standard of measuring weight. “The OptiVol performed much better than daily weight monitoring,” Dr. Abraham said. The sensitivity was 22 percent with weight measurement, compared to 76 percent with OptiVol. “We probably should not be as dependant on daily weight, but it is a standard of care because we haven’t had anything better.”

However, OptiVol is only an indicator and should not be used as a sole diagnostic tool. “It can’t be used in isolation, you can’t base your decision solely on the device data,” Dr. Abraham said. “It’s another piece of the monitoring data that goes into the clinical decision making.”

“We have a very large heart failure management program at OSU, with about 3,000 to 4,000 patients, many using the OptiVol technology,” he said.

No study has been conducted to evaluate if the feature lowers hospitalizations. However, Dr. Abraham said his experience with patients at OSU has shown a reduction in hospitalizations in some patients.

Related Content

Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
iRhythm and Stanford Researchers Develop Deep Learning-Based Cardiac Arrhthymia Detection Algorithm
News | Artificial Intelligence| July 11, 2017
iRhythm Technologies Inc. announced a collaboration with the Stanford Machine Learning Group that has resulted in the...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillators (ICD)| July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Medtronic Reactive ATP Therapy Slows Progression of Atrial Fibrillation in Real-World Population
News | Atrial Fibrillation| July 03, 2017
Medtronic recently announced that its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in...
Overlay Init